Layered Unitary Dosage Forms Patents (Class 424/472)
  • Patent number: 10966937
    Abstract: The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH/tonicity adjustment agent.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: April 6, 2021
    Assignee: Cytometix, Inc.
    Inventors: Lane Brostrom, Henry Bordas-Murphy, John R. Falck
  • Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Patent number: 10835497
    Abstract: The present invention relates to a rivastigmine-containing sustained-release pharmaceutical composition and, more specifically, to a rivastigmine-containing sustained-release pharmaceutical composition, which is a sustained-release preparation containing a pH-dependent delayed release phase, wherein, by controlling the release of the pharmaceutical composition to be minimized in the stomach at the initial stage of administration, the pharmaceutical composition can lower the maximum blood concentration (Cmax) compared with existing products while arriving at an effective blood concentration, thereby reducing side effects, and thereafter, maintaining the effective blood concentration through the sustained-release of main ingredients.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: November 17, 2020
    Assignee: NAVIPHARM CO., LTD.
    Inventors: Sang Geun Park, Hye Gyeong Shin, Jeong Woo Bae, Hyun Ju Choi
  • Patent number: 10835541
    Abstract: The present invention provides a tablet showing high stability of the active ingredients (potassium-competitive acid blocker and acetylsalicylic acid) and stably and rapidly expressing the pharmacological effects of the active ingredients after administration. The present invention provides a tablet containing an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains a potassium-competitive acid blocker free of enteric coating.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 17, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Arisa Maeda, Yuichi Sugiyama, Yoshihiro Uchiyama
  • Patent number: 10772917
    Abstract: Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 15, 2020
    Assignee: CCS VENTURES LIMITED
    Inventors: Timothy J. Kieffer, Jennifer E. Bruin
  • Patent number: 10688052
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Patent number: 10688051
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES LLC
    Inventors: Manish S. Shah, Ray Diflaco
  • Patent number: 10653686
    Abstract: The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: May 19, 2020
    Assignee: PARKINSON'S INSTITUTE
    Inventor: Arasteh Ari Azhir
  • Patent number: 10646481
    Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: May 12, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D. J. Grootenhuis, Martyn Botfield, Alfredo Grossi
  • Patent number: 10617559
    Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 14, 2020
    Assignee: Lynthera Corporation
    Inventors: Arthur Jing-Min Yang, Roman C. Domszy, Jeffry Chung-Hwang Yang
  • Patent number: 10532030
    Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: January 14, 2020
    Assignee: LOCL PHARMA, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 10426724
    Abstract: Combinations of a first generation antihistamine for a quick onset with a maintenance dosage amount of a second or third generation antihistamine, along with an additional active agent such as a decongestant, a cough suppressant (an antitussive), a leukotriene receptor antagonist, a 5-lipoxygenase inhibitor, a bronchodilator, an expectorant, or a combination thereof, are disclosed. Methods of using such combinations by concomitant administration, either in the form of a single composition or multiple compositions, are further disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 1, 2019
    Assignee: APTAPHARMA INC.
    Inventors: Siva Rama K. Nutalapati, Prahlad Patel, Nisha Sureshbhai Patel
  • Patent number: 10251910
    Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Hope Medical Enterprises, Inc.
    Inventors: Craig Sherman, Anthony James Lepine, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
  • Patent number: 10226428
    Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a swellable composition located in an immediate vicinity of one or more preselected surfaces. The coating comprises a defect wherein said defect is not a passageway through the preselected portion of the coating and operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 12, 2019
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
  • Patent number: 10213387
    Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 26, 2019
    Assignee: Sun Pharma Advanced Research Company Ltd.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Amarjit Singh
  • Patent number: 10149822
    Abstract: Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. Such compositions may be in the form of a liquid composition and include a plurality of pharmaceutical ingredients and a plurality of botanical ingredients.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 11, 2018
    Assignee: THE FIX, LLC
    Inventors: Michael K. Allio, Stephen Lane, Marco Wo
  • Patent number: 10076498
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 18, 2018
    Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 10076499
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 18, 2018
    Assignees: Purdue Pharma L.P., Purdue Pharmaceuticals L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9901640
    Abstract: A modified release levodopa dosage form.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: February 27, 2018
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • Patent number: 9884022
    Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: February 6, 2018
    Assignee: LUPIN LIMITED
    Inventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
  • Patent number: 9844538
    Abstract: A method of alleviating or treating a condition which can be alleviated or treated by administering hyoscyamine comprises administering to a subject in need thereof a pharmaceutical dosage form which comprises at least one of hyoscyamine and a pharmaceutically acceptable salt thereof. The dosage form comprises two or more hyoscyamine formulations, at least one of the formulations being an immediate release formulation and at least one other one being a controlled release formulation.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 19, 2017
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Viswanathan Srinivasan, Ralph Brown, David Brown, Himanshu Patel, Juan Carlos Menendez, Somphet Peter Suphasawud
  • Patent number: 9840456
    Abstract: The present invention relates to a process for the preparation of dimethyl fumarate, a compound of formula I, in a purity of at least 99.0% as determined by HPLC, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: December 12, 2017
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Shekhar Bhaskar Bhirud, Kumar Hari Bhushan, H M Veerabhadra Swamy, Dilipkumar Jibhau Patil, Avikumar Digambar Dabe
  • Patent number: 9814722
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: November 14, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Patent number: 9789068
    Abstract: It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 17, 2017
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Yumio Kudou, Kuniomi Warabino, Hiromitsu Ito
  • Patent number: 9782359
    Abstract: The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: October 10, 2017
    Assignee: EURO-CELTIQUE S.A.
    Inventors: Alexander Oksche, Kevin J. Smith, Derek Prater, Malcolm Walden, Will Heath, Bernard Kennedy, Vanessa Addison
  • Patent number: 9775808
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 3, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9775837
    Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 3, 2017
    Assignee: CHARLESTON LABORATORIES, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 9775811
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 3, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9775810
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 3, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9775809
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 3, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9775812
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: October 3, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9770417
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: September 26, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9770416
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: September 26, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9763933
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: September 19, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9763886
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: September 19, 2017
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9694007
    Abstract: An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: July 4, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Jong Soo Woo, Jae Hyun Park, Yong Il Kim, Young Jun Na, Min Jung Kim, Yun Ah Lee
  • Patent number: 9668915
    Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: June 6, 2017
    Assignee: DOSE MEDICAL CORPORATION
    Inventors: David Haffner, Ken Curry, Harold Heitzmann, David Applegate
  • Patent number: 9662335
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 30, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Patent number: 9597338
    Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: March 21, 2017
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Jenny Louie-Helm, John N. Shell
  • Patent number: 9545384
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a non-ionizable cellulosic polymer, and TPGS.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: January 17, 2017
    Assignee: Bend Research, Inc.
    Inventor: Warren Kenyon Miller
  • Patent number: 9504654
    Abstract: The present invention is directed to immediate release film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain medium chain glycerides as detackifiers. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is polyvinyl alcohol and the medium chain glycerides are mixtures of caprylic (8 carbon chain) and capric (10 carbon chain) mono- and diesters of glycerin. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: November 29, 2016
    Assignee: BPSI HOLDINGS, LLC
    Inventors: Jason Teckoe, Bradley J. Prusak, Jeffrey R. Gimbel, Daniel To
  • Patent number: 9421188
    Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: August 23, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
  • Patent number: 9415083
    Abstract: A method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: August 16, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Stefan Patrick Massimino, Gary Mitchell Davenport, Michael Griffin Hayek, George Roth, Donald K. Ingram
  • Patent number: 9345694
    Abstract: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 24, 2016
    Assignees: Cornell Research Foundation, Inc., The Research Foundation of the City University of New York
    Inventors: Rajiv R. Ratan, Marie T. Filbin
  • Patent number: 9339471
    Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 17, 2016
    Assignee: E5 PHARMA, LLC
    Inventors: Robert J. Edwards, Chih-Ting Huang, Nam-Mew Pui
  • Patent number: 9314454
    Abstract: The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a composition containing the above-mentioned components (a) and (b) by an agitation granulation method, and compression-molding the obtained granulation product. The invention also provides a method of producing an orally disintegrating tablet substantially free of a starch disintegrant, including steps of granulating a composition containing the above-mentioned components by an agitation granulation method, and compression-molding the obtained granulation product.
    Type: Grant
    Filed: December 26, 2008
    Date of Patent: April 19, 2016
    Assignee: Sawai Pharmaceutical Co., Ltd.
    Inventors: Tomonori Okumura, Nobuko Hamaguchi, Yasufumi Okamura
  • Patent number: 9301874
    Abstract: Lacrimal inserts such as punctal plugs may be utilized for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured for controlled, pulsatile release into the eye.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: April 5, 2016
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Bret A. Coldren, Peter Paul Willem Leonard Van Den Bekerom, Antonius Wilhelmus Maria De Laat, Johannes Wilhelmus Weekamp, Victor Lust, Gerald Yewey
  • Patent number: 9265757
    Abstract: Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: February 23, 2016
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati
  • Patent number: 9254266
    Abstract: The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over extended periods of time, relative to uncoated pharmaceuticals.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: February 9, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Lian Yu, Melgardt M. De Villiers, Tian Wu
  • Patent number: 9220698
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: December 29, 2015
    Assignees: Pozen Inc., Horizon Pharma USA, Inc.
    Inventors: Brian Ault, Mark Sostek, Everardus Orlemans, John R. Plachetka